Pharmaceutical

Antengene and Hansoh partner to commercialise XPOVIO in China

Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.

Aug 12, 2023 - 20:00
Antengene and Hansoh partner to commercialise XPOVIO in China
Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.
Read the original article

Tags:

Previous Article

Absci and Caltech receive grant to develop HIV therapeutic vaccine

Next Article

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Datopotamab deruxtecan by Daiichi Sankyo for Transition...

Apr 23, 2024

STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy

STAT+: Judge dismisses Novo Nordisk lawsuit over compou...

Oct 6, 2023

Opinion: Smoke from Canadian wildfires shows outdoor workers need air quality protections

Opinion: Smoke from Canadian wildfires shows outdoor wo...

Jun 28, 2023